Skip to main content
. Author manuscript; available in PMC: 2009 Apr 8.
Published in final edited form as: Dev Neurobiol. 2008 Apr;68(5):632–644. doi: 10.1002/dneu.20609

Figure 1.

Figure 1

A: Timeline of treatments; animals were given 17β-estradiol benzoate (EB; 20 μg, s.c) or vehicle 24 h before MFB 6-OHDA lesions. Lateral ventricle (icv) administration of IGF-1 (100 μg/mL) or aCSF were administered 5 min after 6-OHDA lesions. EB and IGF-1 treated groups received icv (0.1 μg/μL of PD98059; MAPK/ERK inhibitor or LY294002; PI3K/Akt inhibitor) 5 min after 6-OHDA lesions. Control lesion animals received icv (0.1 μg/μL of PD98059 or LY294002) 5 min after 6-OHDA lesions. IGF-1 and inhibitors were continuously infused for 7 days. B: Percent use of impaired (contralaral) forelimb, either alone or in combination with nonimpaired (ipsilateral) forelimb for contacting the wall of the cylinder (limb-use asymmetry cylinder test) during a rearing posture 26 h before lesion (pretest) and measurements were obtained again on the sixth day after 6-OHDA lesions. Values expressed as mean percentage ± S.E.M of impaired forelimb usage to the total number of limb contacts with the cylinder wall. Each value is calculated from 5 to 7 animals. * p < 0.05 compared to pretest, one-way ANOVA; Student Newman-Keuls posthoc.